Diabetic Nephropathy Biomarker Development Service
The precise development of biomarkers for diabetic nephropathy provides a key basis for early warning, disease monitoring, efficacy assessment, and prognostic evaluation of this condition. Ace Therapeutics provides biomarker development services for diabetic nephropathy, leveraging our extensive technical experience and expertise in diabetes research and preclinical modeling. We are committed to helping our clients explore valuable biomarkers through innovative technologies and professional services to enhance the diagnosis and treatment of diabetic nephropathy.
Introduction to Biomarkers of Diabetic Nephropathy
It is important to explore relevant biomarkers for early diagnosis of diabetic nephropathy. Currently, clinical diagnostic markers for diabetic nephropathy have many limitations, including the late appearance of proteinuria during disease progression, the occasional absence of proteinuria in typical diabetic nephropathy cases, and the inaccuracy of eGFR measurement. Therefore, it is crucial to characterize current biomarkers for diabetic nephropathy from multiple perspectives, including diabetic nephropathy physiopathology, pathogenesis, and histological techniques.
Fig. 1 The current biomarkers of DN from multiple perspectives. (Chen, Y.; et al., 2025)
Diabetic Nephropathy Biomarker Development Services at Ace Therapeutics
Building on our validated strengths in biospecimen processing and analysis, advanced analytics, and regulatory-compliant research design, Ace Therapeutics provides customized biomarker solutions for diabetic nephropathy. Our solutions span from the discovery of novel molecular signatures to the preclinical validation of diagnostic and therapeutic response markers.
DN biomarker screening services
- Sample collection and processing: We accept diverse biospecimens from diabetic nephropathy (DN) cases, including whole blood, urine, and renal tissue biopsies. Employing specialized protocols for cryopreservation, centrifugation, and nucleic acid stabilization, our standardized processing procedures ensure sample integrity meets stringent experimental requirements, establishing reliable foundations for downstream multi-omics analyses.
- High-throughput screening: We utilize high-throughput technologies such as transcriptome sequencing, proteomics analysis, metabolomics analysis, etc., to comprehensively analyze biological samples. Potential biomarkers are initially identified by screening for genes, proteins or metabolites that are significantly differentially expressed between individuals with diabetic nephropathy and the healthy population.
- Bioinformatics analysis: We use bioinformatics analysis tools and algorithms to deeply mine the data obtained from high-throughput screening. Through differential gene enrichment analysis, protein-protein interaction network construction, metabolic pathway analysis, etc., we screen out the biomarkers that are closely related to the pathological mechanism of diabetic nephropathy and have potential clinical application value.
DN biomarker validation services
- Cellular level validation: In cellular models, we investigate the function of potential biomarkers by technical means such as gene editing, overexpression or knockdown. We observe their effects on the biological behaviors of renal cell proliferation, apoptosis, inflammatory response, extracellular matrix metabolism, etc., and preliminarily validate the correlation between biomarkers and the development of diabetic nephropathy.
- Animal model validation: We use animal models of diabetic nephropathy to examine changes in the expression of potential biomarkers in vivo and their correlation with renal pathological damage. By comparing the levels of biomarkers in animal models at different disease stages, we assessed their potential as indicators for monitoring disease progression.
- Clinical sample validation: We conduct large-scale validation of potential biomarkers through ELISA, immunohistochemistry, real-time fluorescence quantitative PCR and other techniques to analyze their value in DN diagnosis, disease assessment, and efficacy prediction.
DN biomarker translational research
Assay development: We develop simple, rapid, and accurate assays leveraging biomarker characteristics, including in vitro diagnostic kits based on immunoassays and novel molecular detection technologies, to provide robust technical support for the clinical application of biomarkers.
Advantages of Our Diabetic Nephropathy Biomarker Development Services
- Full-process professional services
We provide one-stop services from biomarker screening, validation to translational research, strictly following standardized processes and quality control systems.
- Cross-species model validation system
We provide STZ rat, db/db mouse and non-human primate models to help clients validate the reliability of DN biomarkers.
- Multi-omics + AI-driven efficient discovery
We integrate proteomic, metabolomic and single-cell sequencing technologies to screen for differentially expressed markers (e.g., urinary exosomal miRNA-146a, plasma sTNFR1), and optimize marker combinations in combination with AI algorithms.
Ace Therapeutics leverages its extensive experience and industry-wide network to streamline the biomarker development timeline from discovery to clinical validation. Contact us today to explore customized biomarker development strategies; our cross-functional team is dedicated to accelerating your precision medicine initiatives through validated technical pathways.
References
- Chen, Y.; et al. Biomarkers: New Advances in Diabetic Nephropathy. Natural Product Communications. 2025, 20(2): 1934578X251321758.
- Thippakorn, C.; et al. Proteomic and bioinformatic discovery of biomarkers for diabetic nephropathy. EXCLI journal. 2018, 17: 312.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
